Chapter 2: Development of Recombinant Canarypox Viruses Expressing Immunogens

GARANZINI, DEBORA; DEL MEDCICO ZAJAC, M. PAULA; CALAMANTE, GABRIELA

Recombinant Virus Vaccines. Methods and Protocols

Springer

Año: 2017; p. 15 - 28

Canarypox viruses (CNPV) are excellent candidates to develop recombinant vector vaccines due to both their capability to induce protective immune responses and their incompetence to replicate in mammalian cells (safety profile). In addition, CNPV and the derived recombinants can be manipulated under biosafety level 1 conditions. There is no commercially available system to obtain recombinant CNPV; however, the methodology and tools required to develop recombinant vaccinia virus (VV), prototype of the Poxviridae family, can be easily adapted. This chapter provides protocols for the generation, plaque isolation, molecular characterization, amplification and purification of recombinant CNPV.